Key Benefits

• Empirical treatment with agents such as cefuroxime axetil may ensure the appropriate use of newer antibacterial agents, potentially preventing the emergence of resistance to these newer drugs
  
  
• Empirical therapy for a range of community-acquired respiratory infections, including those in which ?-lactamase producing strains of common respiratory pathogens are identified as the causative organisms
  
  
• The suspension contains micro-pellets of cefuroxime axetil coated with stearic acid to mask the bitter taste. Difficult to manufacture but marketed by Medreich
  
  
• Both the overall incidence of GI adverse events and the incidence of nausea and vomiting are markedly lower with Axacef (cefuroxime axetil) than with amoxicillin/clavulanic acid
  
  
• Convenience of twice daily dosing improving compliance
  
  
• Cefuroxime is also available as the sodium salt as brand Roxicef for parenteral administration. This permits oral follow through with the same antibiotic, when a change from parenteral to oral therapy is clinically indicated, with the added benefits of a reduction in cost and greater convenience

Indications

• Lower respiratory tract infections e.g. acute bronchitis, acute exacerbations of chronic bronchitis and pneumonia
  
  
• Upper respiratory tract infections e.g. ear, nose, throat infections, such as otitis media, sinusitis, tonsillitis and pharyngitis
  
  
• Genito-urinary tract infections e.g. pyelonephritis, cystitis and urethritis
  
  
• Skin and soft tissue infections e.g. furunculosis, pyoderma and impetigo
  
  
• Gonorrhoea acute uncomplicated gonococcal urethritis, and cervicitis
  
  
• Treatment of early Lyme disease and subsequent prevention of late Lyme disease in adults and children over 12 years old